AstraZeneca:high level results of the ARCTIC trial
24 April 2018 07:00 BST ASTRAZENECA REPORTS RESULTS FROM THE ARCTIC TRIAL IN THIRD-LINE NON-SMALL CELL LUNG CANCER AstraZeneca and MedImmune, its global biologics research and development arm, today announced high-level results from the Phase III ARCTIC trial in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least two prior treatments. This randomised, open-label, multi-centre trial assessed the efficacy and safety of the combination of Imfinzi (durvalumab) plus tremelimumab, as well as Imfinzi and tremelimumab monotherapies,